{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057130","form_type":"8-K","ticker":null,"cik":"0001061027","company_name":"Viracta Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.124718+00:00","generated_at":"2026-06-02T04:44:55.638145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viracta Q1 net loss $9.1M; positive NAVAL-1 trial ORR 50% in EBV+ PTCL","bullets":["Net loss $9.1M ($0.23/shr) vs $12.2M in Q1 2023; cash $39.6M sufficient into late Q1 2025.","NAVAL-1 trial: Nana-val ORR 50%, complete response rate 20% in R/R EBV+ PTCL (n=10); median DoR maturing.","Plan to meet FDA mid-2024 for accelerated approval; Stage 1+2 data expected Q3 2024.","PMDA endorsed direct Japan enrollment into NAVAL-1 without prior Phase 1 safety study.","Phase 1b/2 solid tumor study: RP2D expected H2 2024; dose-optimization cohort by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057130","json":"https://secwatch.observer/filing/0000950170-24-057130.json","markdown":"https://secwatch.observer/filing/0000950170-24-057130.md","text":"https://secwatch.observer/filing/0000950170-24-057130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024057130/0000950170-24-057130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024057130/virx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:44:55.638145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"afc20c16b5ad224b5e5f851dd918492ffd2506b3","claim":"Viracta Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Viracta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024057130/0000950170-24-057130-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}